High Density Lipoprotein Cholesterol in Coronary Artery Disease: When Higher Means Later

Sbrana, Francesco; Puntoni, M.; Bigazzi, Federico; Landi, Patrizia; Sampietro, Tiziana; Rossi, Giuseppe; Rovai, Daniele

doi:10.5551/jat.13201

Cited by 5 publications

(7 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also provided subgroup analyses in whole population as followed: (a) smokers vs non-smokers, (b) diabetics vs non-diabetics, (c) statin-treated vs non-treated patients, and (d) controlled vs uncontrolled hypertensives in order to investigate any differences in HDL-C and PBR 5-9 levels within the above-mentioned groups as well as the relationship between HDL-C and PBR [5][6][7][8][9] in each group separately.…”

Section: Discussionmentioning

confidence: 99%

“…Increased perfusion boundary region (PBR) of the sublingual arterial microvessels (ranging from 5 to 9 µm) using Sideview Darkfield imaging (Microscan, Glycocheck) was measured as a non-invasive accurate index of reduced EG thickness. PBR [5][6][7][8][9] was significantly decreased in group HDL H (P = 0.04). In the whole population, HDL-C was inversely but moderately related to PBR 5-9 (r = −0.22, P = 0.01).…”

mentioning

confidence: 89%

“…5 Moreover, the appearance of coronary artery disease is being delayed by 3-5 years in those patients with elevated HDL-C compared to patients with low or normal HDL-C levels. 6 The endothelial glycocalyx (EG) represents a barrier of glycoproteins and proteoglycans between blood cells and endothelial vascular surface. EG damage, caused by inflammatory or atherogenic factors, leads to enhanced vascular sensitivity to prothrombotic, vasoactive, and atherogenic stimuli and is observed in newly diagnosed untreated hypertensives.…”

mentioning

confidence: 99%

See 2 more Smart Citations

HDL cholesterol levels and endothelial glycocalyx integrity in treated hypertensive patients

Triantafyllidi

Benas

Vlachos

et al. 2018

J of Clinical Hypertension

View full text Add to dashboard Cite

Endothelial dysfunction indicates target organ damage in hypertensive patients. The integrity of endothelial glycocalyx (EG) plays a vital role in vascular permeability, inflammation and elasticity, and finally to cardiovascular disease. The authors aimed to investigate the role of increased HDL cholesterol (HDL‐C) levels, which usually are considered protective against cardiovascular disease, in EG integrity in older hypertensive patients. The authors studied 120 treated hypertensive patients older than 50 years were divided regarding HDL‐C tertiles in group HDLH (HDL‐C ≥ 71 mg/dL, upper HDL‐C tertile) and group HDLL (HDL‐C < 71 mg/dL, two lower HDL‐C tertiles). Increased perfusion boundary region (PBR) of the sublingual arterial microvessels (ranging from 5 to 9 µm) using Sideview Darkfield imaging (Microscan, Glycocheck) was measured as a non‐invasive accurate index of reduced EG thickness. PBR 5‐9 was significantly decreased in group HDLH (P = 0.04). In the whole population, HDL‐C was inversely but moderately related to PBR 5‐9 (r = −0.22, P = 0.01). In a multiple linear regression analysis model, using age, BMI, smoking habit, HDL‐C, LDL‐C, and office SBP, as independent variables, the authors found that BMI (β = 0.25, P = 0.006) independently predicted PBR 5‐9 in the whole population. In older hypertensive patients, HDL‐C ranging between 71 and 101 mg/dL might moderately protect EG and subsequently endothelial function. Future studies in several groups of low‐ or high‐risk hypertensives are needed in order to evaluate the beneficial role of extremely elevated HDL‐C regarding cardiovascular risk evaluation as well as endothelial glycocalyx as a novel index of target organ damage in essential hypertension.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 89%

mentioning

confidence: 99%

See 1 more Smart Citation

HDL cholesterol levels and endothelial glycocalyx integrity in treated hypertensive patients

Triantafyllidi

Benas

Vlachos

et al. 2018

J of Clinical Hypertension

View full text Add to dashboard Cite

show abstract

“…On the other hand, they are not widely used in clinical practice due to the lack of validated methods to assess these parameters, which is also mentioned by experts in existing guidelines 1. We also should not forget other, “less sophisticated”, biochemical markers of cardiovascular risk with proved antioxidative role such as HDL‐C 9, 10, lipoprotein A, 11, C‐reactive protein 12, and other lipid parameters 13, 14, although again in accordance with the guidelines they are of limited importance 1. The interpretation of this study should also take into account relatively small population of patients with most severe coronary artery disease – with multivessel disease – where intense and wider risk profile assessment could be reasonable.…”

Section: Recommendations For Lipid Analyses For Screening For Cardiovmentioning

confidence: 99%

Are we ready to use oxidative stress in clinical practice?

Grabowski

2012

Euro J Lipid Sci & Tech

View full text Add to dashboard Cite

show abstract

“…However, HDL‐C levels are influenced by many factors that also influence CVD risk . Interestingly, Sbrana et al recently concluded that also patients with elevated HDL‐C may develop CVD but later in life . In addition, a recent Mendelian randomization study provides strong evidence that genetic mechanisms raising HDL‐C do not always confer lower risk of myocardial infarction .…”

mentioning

confidence: 99%

ApoA‐I mutations, L202P and K131del, in HDL from heterozygotes with low HDL‐C

Ljunggren

Levels

Turkina

et al. 2014

Proteomics Clinical Apps

View full text Add to dashboard Cite

Purpose Mutations in apolipoprotein A‐I (apoA‐I) may affect plasma high‐density lipoprotein (HDL) cholesterol levels and the risk for cardiovascular disease but little is known about the presence and effects of circulating apoA‐I variants. This study investigates whether the apoA‐I mutations, apoA‐IL202P and apoA‐IK131del, are present on plasma HDL particles derived from heterozygote carriers and whether this is associated to changes in HDL protein composition. Experimental design Plasma HDL of heterozygotes for either apoA‐IL202P or apoA‐IK131del and family controls was isolated using ultracentrifugation. HDL proteins were separated by 2DE and analyzed by MS. Results ApoA‐I peptides containing apoA‐IL202P or apoA‐IK131del were identified in HDL from heterozygotes. The apoA‐IL202P mutant peptide was less abundant than wild‐type peptide while the apoA‐IK131del mutant peptide was more abundant than wild‐type peptide in the heterozygotes. Two‐dimensional gel electrophoresis analyses indicated that, compared to controls, HDL in apoA‐IL202P carriers contained less apoE and more zinc‐α‐2‐glycoprotein while HDL from the apoA‐IK131del heterozygotes contained more alpha‐1‐antitrypsin and transthyretin. Conclusions and clinical relevance Both apoA‐IL202P and apoA‐IK131del were identified in HDL. In heterozygotes, these mutations have markedly differential effects on the concentration of wild‐type apoA‐I in the circulation, as well as the HDL proteome, both of which might affect the clinical phenotype encountered in the heterozygous carriers.

show abstract

High Density Lipoprotein Cholesterol in Coronary Artery Disease: When Higher Means Later

Cited by 5 publications

References 45 publications

HDL cholesterol levels and endothelial glycocalyx integrity in treated hypertensive patients

HDL cholesterol levels and endothelial glycocalyx integrity in treated hypertensive patients

Are we ready to use oxidative stress in clinical practice?

ApoA‐I mutations, L202P and K131del, in HDL from heterozygotes with low HDL‐C

Contact Info

Product

Resources

About